Arrowhead Pharmaceuticals (ARWR) was upgraded by Morgan Stanley from "equal weight" to "overweight". They now have a $100.00 price target on the stock.
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results
Arrowhead Plozasiran Data Supports Triglyceride Reduction And Valuation Upside Potential [Yahoo! Finance]
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
SRPT Stock Surges on Promising Early Results From siRNA Programs [Yahoo! Finance]